摘要 |
Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
|
申请人 |
THE REGENTS OF THE UNIVERSITY OF COLORADO;BUNN, PLAUL, A.;COLDREN, CHRISTOPHER, D.;FRANKLIN, WIBUR, A.;GERACI, MARK, W.;HELFRICH, BARBARA, A.;HIRSCH, FRED, R.;LAPADAT, RAZVAN;SUGITA, MICHIO;WITTA, SAMIR, E. |
发明人 |
BUNN, PLAUL, A.;COLDREN, CHRISTOPHER, D.;FRANKLIN, WIBUR, A.;GERACI, MARK, W.;HELFRICH, BARBARA, A.;HIRSCH, FRED, R.;LAPADAT, RAZVAN;SUGITA, MICHIO;WITTA, SAMIR, E. |